Mesoestetic Pharma Group, a leading pharmaceutical laboratory in the cosmetics and aesthetic medicine sector, has concluded the year 2024 with a turnover of 82.1 million euros, representing a 22% increase compared to the previous year.
This growth is attributed to its management model focused on innovation, development, and research. Looking ahead to 2025, the company expects to exceed 90 million euros in sales. In addition, it will make a historic investment of 30 million euros in the construction of a new building adjacent to its headquarters in the Viladecans Business Park (Barcelona). This expansion will include a 'front office', a logistics center, and a storage area, designed to optimize internal processes and improve operational efficiency.
In 2024, Mesoestetic reinvested 44% of its profits in R&D, focusing on improving facilities, acquiring new equipment, and opening new lines of research in aesthetic medicine and cosmetics.